Organizing pneumonia (OP) is defined as filling of the distal air spaces with buds of granulation tissue progressing from fibrin exudates to lose collagen.1 This pathological pattern may be encountered in different disease processes, such as infection, infarction, certain treatments (eg, chemotherapy) and immune disorders (eg, connective tissue diseases and graft-versus-host disease).2,3 According to its causes or associated diseases, OP can be categorized into OP with a determined cause, OP with undetermined causes but underlying specific or relevant conditions and cryptogenic OP (COP). Unfortunately, there is a lack of distinct features among these three groups.2 The clinical characteristics of OP are similar to those of respiratory infection (with recurrent or persistent fever, dyspnoea, cough, and weakness as the dominant symptoms) and are difficult to differentiate from other pathological processes. The radiological manifestations are also non-specific, exhibiting patchy consolidation and ground-glass opacities. The potentially significant features may be migrating pulmonary infiltrates and less pulmonary fibrosis during follow-up.2
The common pulmonary complications of haematological malignancies are infectious diseases and may be frequently attributed to immune deficiency.4,5 However, non-infectious causes, such as pulmonary oedema, haemorrhage, autoimmune manifestations and pulmonary alveolar proteinosis, could be potential aetiologies for pulmonary infiltrates in patients with haematological malignancies.35 In the last decade, OP has been reported in haematological disorder patients.3,69 Other related factors, including chemotherapy, stem cell transplantation (SCT) and infection, have been previously described with respect to OP in cases of haematological malignancies.3,7,9 Therefore, there is limited information on OP underlying only haematological malignancies or caused by haematological malignancies. Moreover, due to the lack of specific features, it is difficult to distinguish OP from other pulmonary complications associated with haematological malignancies.
To discuss OP associated with haematological malignancies and exclude other related reasons, we conducted this observational study. Some traditional methods, such as antigen and antibody detection, Gram staining, culture and so on. New and promising NGS was also employed to detect pathogens.
This observational study was performed at a 3500-bed tertiary teaching hospital, the Second Xiangya Hospital of Central South University, Changsha, in mid-southern China. This study was approved and supervised by the Medical Research Ethics Committee of the Second Xiangya Hospital, Central South University. No interventions were conducted in this study. On the other hand, clear privacy and identity information of patients, such as name, address, telephone number and ID number (all data), were kept confidential and not described in this study. The study was ranked as not more than the minimum risk and the rights and interests of subject will not be invaded by the Medical Research Ethics Committee of the Second Xiangya Hospital. Therefore, written informed consent was waived. The hospital records database was searched for all cases of OP with haematological malignancies from 1 January 2000 to 1 July 2020. The diagnosis of OP was confirmed by two independent pathologists following the American Thoracic Society/European Respiratory Society statement (2013 update).10 Patients were excluded if they had other related conditions, including chemotherapy, radiotherapy, targeted therapy, SCT, bone marrow transplantation (BMT), cord blood transplantation (CBT) and infection.
To exclude infection, sputum, bronchoalveolar lavage fluid (BALF), blood and bone marrow cultures were conducted in these patients, none of which yielded positive results. 1,3--d-Glucan (G) and galactomannan (GM; in both blood and BALF) tests also did not yield positive results. Interstitial lung diseases (ILDs) induced by connective tissue disease (CTD) were excluded by antigen and antibody detection of CTD. CTD detection included examinations of anti-cyclic citrullinated peptide, rheumatoid factors, antinuclear antibodies, extractable nuclear antigens and anti-cardiolipin antibodies.
The following information was examined: demographics, underlying cancer diagnoses, physical examination and laboratory findings, pulmonary function before OP diagnosis, findings on chest radiography and computed tomography (CT), steroid treatment, use of concurrent treatments, clinical outcomes and follow-up.
The duration of OP diagnosis was defined as the time from symptom onset to the pathological diagnosis of OP. Clinical outcomes during hospitalization were confirmed by two independent pulmonologists, and a favourable clinical response was defined as a complete or partial alleviation of symptoms and signs after 1 week of steroid treatment.
There were 12 patients with a histopathological diagnosis of OP and concomitant diagnosis of a haematological malignancy in our database from 1 January 2000 to 1 July 2020. Before OP onset, seven patients accepted chemotherapy, including one patient who accepted SCT, one who received targeted therapy (eg, rituximab) and three with ongoing infection. The other five patients had OP associated with haematological malignancies, which were the primary pathological processes without any other related reasons. None of these five patients accepted chemotherapy, targeted therapy or SCT. There were three female patients, including one with myelodysplastic syndrome (MDS), one with acute myelogenous leukaemia (AML, M5), and one with multiple myeloma (MM). One of the two male patients had aplastic anaemia (AA), and the other had T cell lymphoma (TCL). The patients ages ranged from 43 to 67 years, and three of them had a smoking history (range from 30 to 80 pack-years).
The five cases of OP associated with haematological malignancies presented symptoms similar to those of pulmonary infection, such as fever, cough and dyspnoea (Table 1). One patient had a history of haemoptysis, which may have been caused by MDS-induced thrombocytopenia. Two of the patients had a history of productive cough with sputum, but all five patients were observed to have moist inspiratory rales. Consistent with the non-fibrosis on CT scan, none of the patients exhibited Velcro rales.
Table 1 Demographic and Clinical Characteristics of OP Associated with Haematological Malignancies
All five OP patients were hospitalized for diagnosis, and all were primarily diagnosed with pulmonary infection. Due to unfavourable responses to antibiotics and immune deficiency, pulmonary aspergillosis was the most frequently considered diagnosis before the diagnosis of OP. All patients were found to have anaemia, and four of them (excluding the patient with TCL) showed hypolymphocytosis in routine blood tests. Interestingly, after the use of steroids, all patients showed improvement of anaemia without treatment for haematological malignancies. Before the diagnosis of OP, all patients accepted anti-infection treatments for more than 4 weeks, including piperacillin-tazobactam, cefoperazone-sulbactam, meropenem, and voriconazole. However, none of them received antiviral treatment, indicating that bacterial and fungal infections were the most frequently considered differential diagnoses in OP associated with haematological malignancies. Furthermore, all five OP patients were admitted to the intensive care unit (ICU) for respiratory failure (Table 1).
All patients underwent high-resolution computed tomography (HRCT) before OP diagnosis, and one of them even underwent positron emission tomography-computed tomography (PET-CT). As in previous studies,8,9,11 there were patchy consolidative opacities and airspace consolidation along the bronchovascular bundle or in the subpleural area on HRCT (Figure 1). However, some uncommonly described findings on HRCT were observed in these cases. One MDS case and one AML case exhibited multiple nodules along the bronchovascular bundle with ground-glass opacity (GGO). The HRCT scan of the MDS case even showed a halo of GGO, which is a typical early sign of pulmonary fungal infection (Figure 2A). Additionally, the AML patient exhibited interlobular septal thickening and a reticulonodular pattern (Figure 2B). Interestingly, both cases progressed rapidly and developed extensive bilateral opacity on HRCT in less than 2 weeks (Figure 2C and D).
Figure 1 The common findings of OP associated with haematological malignancies on HRCT. There were patchy consolidative opacities (black arrow) and airspace consolidation (white arrow) along the bronchovascular bundle or in the subpleural region on HRCT.
Figure 2 HRCT of OP associated with haematological malignancies mimics IPA. (A) The HRCT scan of the MDS case even showed a halo of GGO as a typical early sign of pulmonary fungal infection. (B) The AML case was also observed to exhibit GGO, interlobular septal thickening and reticulonodular patterns. (C and D) show that the lesion rapidly progressed to extensive bilateral opacity in less than 2 weeks from (A and B), respectively.
PET-CT was conducted in TCL patients and showed a high standardized uptake value (SUV) max of the lung and pleura (range from 2.5 to 3.5). However, PET-CT showed a higher SUV max of the retroperitoneal and intraperitoneal lymph nodes (>7.5).
Since OP is a rare disease without distinct symptoms and is defined by pathological pattern, it takes a long time to diagnose this condition.2 The duration from onset to OP diagnosis was extensive, ranging from 1 to 6 months in the 5 OP cases. OP was frequently diagnosed by lung biopsy, including bronchoscopic and CT-guided percutaneous biopsy. All five patients underwent bronchoscopic biopsy, and the results were confirmed by two independent pathologists (Figure 3). Due to the subpleural lesion and limitation of the biopsy sample, one TCL patient failed to obtain a proper diagnosis for the lung lesions even after 2 times of bronchoscopic biopsies. Finally, the OP diagnosis was confirmed via CT-guided percutaneous biopsy.
Figure 3 Pathological findings in OP associated with haematological malignancies. (A) Lung specimens stained with haematoxylin and eosin (100) showed amorphous material in the alveoli (black arrow) and infiltration of lymphocytes in the alveolar septum. (B and C) show immunohistochemical staining with vimentin (Vim) and smooth muscle actin (SMA), respectively. Cytoplasmic-positive cells were fusiform and considered fibroblasts, which were in the alveoli.
Cytological detection was conducted in BALF from the five patients, and no malignant cells were found. Four of them had differential cell counts and T cell subsets in BALF, except for the MM case. The ratios of lymphocytes ranged from 15% to 30%, and the ratios of CD4+/CD8+ T cells ranged from 1.5 to 3.0 (Table 1). However, the ratios of neutrophil were under 15% in all 4 cases. In addition, no malignant cells were observed in the alveolar space or wall from the biopsy sample.
Although bronchoscopy revealed purulent sputum in the TCL patient with OP, the pathogen-detection results were negative in sputum and BALF. Bronchoscopy of the other four patients revealed only a few secretions without oedema and congestive mucosa in the airways. To detect possible pathogens, next-generation sequencing (NGS) technology was conducted in blood and BALF from the MDS and AML cases. The sequence analysis did not identify causative pathogens for the two cases.
Before steroid treatment, all AA and MDS patients suffered severe anaemia, and the AML case suffered mild neutropenia. Because all of five patients were severe cases and admitted into ICU, they could not finish the lung function test. All of them lack of the lung function data before OP diagnosis.
Once the five patients were diagnosed with OP, all were treated with intravenous steroids (methylprednisolone, 40 mg/day) for more than 1 week. Fever and cough were the earliest and most frequently improved symptoms after steroid treatment. The five patients underwent steroid (intravenous and oral) treatment for 36 months. During follow-up, we found that the respiratory symptoms and radiological abnormalities were completely reversed after 13 months of steroid use (Table 1). One patient died due to AA at the 13th month of follow-up, and the other four patients survived during follow-up. Interestingly, none of the OP case series relapsed.
Due to agranulocytosis, the AML patient was treated with voriconazole and cefoperazone-sulbactam after OP diagnosis. The other four OP patients discontinued antifungal treatment after no evidence of fungal infection was found. Because of mild neutropenia, AA and TCL patients received piperacillin-tazobactam treatment after their OP diagnosis.
After recovery of OP, two of them suffered severe anaemia, one suffered thrombocytopenia, and one was dead. And MDS patient was observed with an improved of anaemia after OP treatment (haemoglobin 5793 g/L). Only the MDS patients finished the lung function test after OP treatment. The results showed forced expiratory volume in first second/forced vital capacity (FEV1/FVC) 76.0% and FEV1/prediction 90.6% after bronchodilation use. The pulmonary diffusion function of the MDS was valued with diffusion capacity for carbon monoxide of lung single-breath method (DLCO2-sb), and the results of DLCO2 and DLCO2/ VA (alveolar volume) were normal (7.98 and 1.38 mmol/min/kPa/L).
Since the aetiology of OP is multifactorial, OP with haematological malignancies could be caused by anti-cancer drugs,12,13 transplantation (SCT, BMT and CBT),11,14 immunodeficiency-induced infection and secondary CTD.2,8,9 The authors summarized the cases of five OP patients with only haematological malignancies after excluding other risk factors, implying that haematological malignancies may be a causative factor for OP.
The patients ages in our study ranged from 43 to 68 years, and the average age in OP with haematological malignancies was 52.3 years,8 indicating that younger patients with haematological malignancies may be less likely to develop OP.11 In previous studies, only 55 OP patients were provided rough haematological diagnosis and divided into 3 groups of haematological malignancies (Table 2), 20 cases of lymphoma (36.4%), 22 cases of leukaemia (40%) and 13 cases of MDS (23.6%). Our study demonstrated that AA and MM were two new underlying haematological diseases. Our results also showed an improvement in anaemia following reversal of OP, indicating that OP may aggravate anaemia in haematological malignancies. Unlike previous study of OP with haematological malignancies,9 all patients in our study were admitted to the ICU, and three of them underwent mechanical ventilation. A previous study reported that OP cases with multiple possible causes in other malignancies were also observed with a high ratio of severe cases.8 However, OP with other benign causes was described with a favourable prognosis.2 It is possible that OP associated with haematological malignancies is more likely to develop into a severe case than OP with benign underlying diseases, suggesting that physicians should exercise caution in treating OP patients with haematological malignancies.
Table 2 Summary of Previous Reports on Organizing Pneumonia Associated with Haematological Malignancy
Previous studies8,9,11 demonstrated that radiological findings were not distinctive, and the authors also found patchy consolidative opacities and airspace consolidation along the bronchovascular bundle or in the subpleural region on HRCT. However, two patients in our case series and 7 OP patients in another study15 were observed to exhibit multiple nodules along the bronchovascular bundle with GGO on HRCT, which were described as highly indicative of invasive pulmonary aspergillosis (IPA). As the disease progressed, the two patients in our study developed extensive consolidation in 1 week. The above findings confirmed that the radiological findings of OP associated with haematological malignancies lacked a unique pattern and could mimic some other diseases, such as IPA. Therefore, physicians cannot exclude OP only by radiological findings in haematological malignancy patients, especially in patients with a poor response to anti-infection treatment. Additionally, there is limited information on PET-CT findings in OP. The SUVmax of the OP lesion in TCL patients was increased but was still lower than that of the malignant lesion, indicating that pulmonary lesions may be different from lymphadenopathy. To discuss whether OP and malignant or metastatic lesions could be distinguished through PET-CT, there is a need of further study with larger sample size.
This study revealed that OP patients with haematological malignancies had similar symptoms to those with pulmonary infection (Table 2), with a long duration from the onset to the diagnosis of OP. Due to the lack of distinctive symptoms and examinations, it is difficult to distinguish OP from infection. Therefore, bronchoscopic, CT-guided percutaneous and surgical lung biopsies were employed in the diagnosis of OP with haematological malignancies (Table 2). At the beginning of the twenty-first century, surgical lung biopsy was more frequently used1517 (Table 2). However, in the last ten years, bronchoscopic and CT-guided percutaneous biopsies have been more frequently used.12,18,19 Haematological malignancies may lead to contraindications for surgery, such as severe thrombocytopenia and anaemia. The five cases of OP associated with haematological malignancies were confirmed through bronchoscopic and CT-guided biopsy, and all of these patients tolerated the minimally invasive biopsy well. This case series revealed that bronchoscopic and CT-guided percutaneous biopsies were safe and effective in the diagnosis of OP with haematological malignancies. Because of the limited sample size and undiagnosed pathological pattern, the OP patient with underlying TCL in our study underwent bronchoscopic biopsy 2 times, and the diagnosis was confirmed through CT-guided percutaneous biopsy. It seems that CT-guided percutaneous biopsy may be more effective in subpleural lesions than bronchoscopic biopsy.
As described in a previous study,2 steroid treatment led to a favourable outcome in this case series. To discuss steroid treatment in OP associated with haematological malignancies, the authors searched for OP and haematological malignancies in PubMed (Table 2). Most of the identified studies used steroids to treat OP and demonstrated a favourable response. However, other studies found that OP with haematological malignancies could be steroid resistant and improved with SCT18 or without treatment.7 The follow-up demonstrated unfavourable clinical outcomes associated with non-steroidal treatment,7 indicating that observation without treatment may not be suitable for OP with haematological malignancies. Furthermore, our study excluded other possible causative factors, such as infection, could progress after steroid treatment. For the above reasons, the authors suggest that steroids may be the first-line drug treatment for OP associated with haematological malignancies. Due to the limitation of sample size, a prospective study with larger sample size might provide stronger evidence.
Collectively, our findings provide support that haematological malignancies may be a causative factor for OP and that biopsy may be an effective and safe method to confirm the diagnosis. Although OP associated with haematological malignancies may more frequently develop into severe cases, OP lesions seem to be steroid responsive with favourable outcomes during follow-up.
The datasets analysed during the current study are not publicly available to protect patient privacy but are available from the corresponding author on reasonable request.
The study was approved and supervised by the Medical Research Ethics Committee of the Second Xiangya Hospital, Central South University. Informed consent was waived. This research was performed in accordance with the Declaration of Helsinki.
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
This study was supported by National Key Clinical Specialist Construction Programs of China; the National Natural Science Foundation of China (81370143, 81170036, 81400032); Beijing Bethuen Charitable Foundation (BJ-RW2020011J) and the Natural Science Foundation of Hunan Province (09JJ3036, 2019JJ50877).
The authors declare that they have no conflicts of interest.
1. Enright H, Jacob HS, Vercellotti G, et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol. 1995;91(2):403408. doi:10.1111/j.1365-2141.1995.tb05310.x
2. Cordier J-F. Organising pneumonia. Thorax. 2000;55(4):318328. doi:10.1136/thorax.55.4.318
3. Lamour C, Bergeron A. Non-infectious pulmonary complications of myelodysplastic syndromes and chronic myeloproliferative disorders. Rev Mal Respir. 2011;28(6):e1827. doi:10.1016/j.rmr.2009.04.001
4. Hildebrand FL, Rosenow EC, Habermann TM, et al. Pulmonary complications of leukemia. Chest. 1990;98(5):12331239. doi:10.1378/chest.98.5.1233
5. Pennington JE, Feldman NT. Pulmonary infiltrates and fever in patients with hematologic malignancy: assessment of transbronchial biopsy. Am J Med. 1977;62(4):581587. doi:10.1016/0002-9343(77)90421-1
6. Inoue D, Marumo S, Ishii H, et al. Secondary pulmonary alveolar proteinosis during corticosteroid therapy for organising pneumonia associated with myelodysplastic syndrome. BMJ Case Rep. 2019;12(9). doi:10.1136/bcr-2019-231055
7. Kobara Y, Amemiya Y, Mieno T, et al. Clinical study of three myelodysplastic syndrome (MDS) patients with BOOP-like pulmonary disease. Nihon Kokyuki Gakkai Zasshi. 2000;38(8):605609.
8. Mokhtari M, Bach PB, Tietjen PA, et al. Bronchiolitis obliterans organizing pneumonia in cancer: a case series. Respir Med. 2002;96(4):280286. doi:10.1053/rmed.2001.1269
9. Daniels CE, Myers JL, Utz JP, et al. Organizing pneumonia in patients with hematologic malignancies: a steroid-responsive lesion. Respir Med. 2007;101(1):162168. doi:10.1016/j.rmed.2006.03.035
10. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733748. doi:10.1164/rccm.201308-1483ST
11. Tanaka N, Kunihiro Y, Yujiri T, et al. High-resolution computed tomography of chest complications in patients treated with hematopoietic stem cell transplantation. Jpn J Radiol. 2011;29(4):229235. doi:10.1007/s11604-010-0544-8
12. Mankikian J, Lioger B, Diot E, et al. Pulmonary toxicity associated with the use of lenalidomide: case report of late-onset acute respiratory distress syndrome and literature review. Heart Lung. 2014;43(2):120123. doi:10.1016/j.hrtlng.2013.11.007
13. Alnimer Y, Salah S, Abuqayas B, et al. Azacitidine-induced cryptogenic organizing pneumonia: a case report and review of the literature. J Med Case Rep. 2016;10(1):15. doi:10.1186/s13256-016-0803-0
14. Uhlving HH, Andersen CB, Christensen IJ, et al. Biopsy-verified bronchiolitis obliterans and other noninfectious lung pathologies after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(3):531538. doi:10.1016/j.bbmt.2014.12.004
15. Kim K, Lee MH, Kim J, et al. Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Am J Hematol. 2002;71(2):7579. doi:10.1002/ajh.10168
16. White DA, Wong PW, Downey R. The utility of open lung biopsy in patients with hematologic malignancies. Am J Respir Crit Care Med. 2000;161(3):723729. doi:10.1164/ajrccm.161.3.9904016
17. Dunn JC, West KW, Rescorla FJ, et al. The utility of lung biopsy in recipients of stem cell transplantation. J Pediatr Surg. 2001;36(8):13021303. doi:10.1053/jpsu.2001.25799
18. Asano T, Fujii N, Niiya D, et al. Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation. SpringerPlus. 2014;3(1):15. doi:10.1186/2193-1801-3-3
19. Vieira AL, Vale A, Melo N, et al. Organizing pneumonia revisited: insights and uncertainties from a series of 67 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(2):129138. doi:10.36141/svdld.v35i2.6860
20. Dai M-S, Lee S-C, Ho C-L, et al. Impact of open lung biopsy for undiagnosed pulmonary infiltrates in patients with hematological malignancies. Am J Hematol. 2001;68(2):8790. doi:10.1002/ajh.1158
21. Wohlrab JL, Anderson ED, Read CA. A patient with myelodyplastic syndrome, pulmonary nodules, and worsening infiltrates. Chest. 2001;120(3):10141017. doi:10.1378/chest.120.3.1014
22. Karamlou K, Gorn AH. Refractory sweet syndrome with autoimmune organizing pneumonia treated with monoclonal antibodies to tumor necrosis factor. J Clin Rheumatol. 2004;10(6):331335. doi:10.1097/01.rhu.0000147053.60795.46
23. Garg R, Soud Y, Lal R, et al. Myelodysplastic syndrome manifesting as sweets syndrome and bronchiolitis obliterative organizing pneumonia. Am J Med. 2006;119(11):e57. doi:10.1016/j.amjmed.2006.03.032
24. Tomonari A, Tsukada N, Takahashi S, et al. Early-onset pulmonary complication showing organizing pneumonia pattern following cord blood transplantation in adults. Int J Hematol. 2007;85(4):364366. doi:10.1532/IJH97.07016
25. Kamiya H, Ishikawa R, Moriya A, et al. Disseminated cryptococcosis complicated with bilateral pleural effusion and ascites during corticosteroid therapy for organizing pneumonia with myelodysplastic syndrome. Intern Med. 2008;47(22):19811986. doi:10.2169/internalmedicine.47.0898
26. Tzelepis E, Kampolis CF, Vlachadami I, et al. Cryptogenic organizing pneumonia in Sweets syndrome: case report and review of the literature. Clin Respir J. 2016;10(2):250254. doi:10.1111/crj.12206
Read more here:
- How Bone Marrow and Stem Cells are Collected | BMT Infonet - January 16th, 2022
- How Much Does Cord Blood Banking Cost? - January 16th, 2022
- Exploring the relationship between stem cells and COVID-19 - News-Medical.Net - January 16th, 2022
- Private cord blood bank CellSave Arabia receives the first DHA license to operate as a Cord Blood and Stem Cell Center - Gulf News - January 16th, 2022
- Where Stem Cells Are Found, & the Difference That Makes ... - January 16th, 2022
- North America Stem Cell Umbilical Cord Blood Market 2022: Industry Trends, Growth, Size, Segmentation, Top Players, Share, Upcoming Demand, Regional,... - January 7th, 2022
- A donation that could help cure blood cancer - EurekAlert - January 7th, 2022
- Amgen, Generate ink potential $1.9B-plus agreement in protein therapeutics - BioWorld Online - January 7th, 2022
- Josh Gelman, CBS News producer who embodied bravery, hope, dies of cancer - WSGW - January 7th, 2022
- January 2022: 2021 Papers of the year - Environmental Factor Newsletter - January 3rd, 2022
- Next Chapters: How Northern California blood recipients are doing years after donors helped save their lives - KCRA Sacramento - January 3rd, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - December 31st, 2021
- UK's Leading Umbilical Cord Blood Stem Cell Bank | Cells4Life - December 29th, 2021
- zge zpirinci: Why the Love at Second Sight actress keeps her daughters umbilical cord blood - Market Research Telecast - December 29th, 2021
- Autologous infusion of bone marrow and mesenchymal stromal c | COPD - Dove Medical Press - December 29th, 2021
- National Advertising Division Recommends Cryo-Cell Discontinue or Modify Certain Health-Related Claims for Cord Blood Banking and Treatment Services -... - December 23rd, 2021
- Cord Blood and Medical Misinformation: The Big Business of ... - December 21st, 2021
- Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021 - Yahoo Finance - December 19th, 2021
- Immunohematology Market Size to Grow by USD 907.43 Mn| Growing Demand for Blood Banks and their Potential to Increase Sales will Present Significant... - December 12th, 2021
- Umbilical cord - Wikipedia - December 12th, 2021
- Injectable gel repairs severe spinal cord injuries and enables mice to walk - Big Think - December 12th, 2021
- Regenerative Medicine Market Size 2021 Industry Share, Global Trend, In-Depth Players Analysis, Revenue, and Recovery, Supply, Growth, Regional... - December 11th, 2021
- Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells... - December 11th, 2021
- Stem Cell/Cord Blood Banking Global Market Report 2021: COVID-19 Impact Analysis, Growth and Forecasts to 2030 - ResearchAndMarkets.com - Business... - December 9th, 2021
- Unproven stem cell treatment industry in the USA: a concerning boom - BioNews - November 22nd, 2021
- Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate... - November 22nd, 2021
- Leukaemia: how can stem cells help? | Eurostemcell - November 16th, 2021
- Induced Pluripotent Stem Cells and Their Potential for ... - November 16th, 2021
- CELULARITY INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - November 13th, 2021
- In an Astonishing Feat, a New Drug Reversed Paralysis in Mice With Spinal Cord Injury - ScienceAlert - November 13th, 2021
- High Induction of IL-6 Secretion From hUCMSCs Optimize the Potential of hUCMSCs and TCZ as Therapy for COVID-19-Related ARDS - DocWire News - November 13th, 2021
- PRESS RELEASE : Vita 34 again increases sales and margins in the third quarter - marketscreener.com - November 13th, 2021
- Hiltzik: The battle against unlicensed stem cell clinics - Los Angeles Times - November 7th, 2021
- Cord blood cell transplantation and curcumin administration tested as therapy of Tay-Sachs disease - EurekAlert - November 7th, 2021
- Cryoviva Singapore Gets AABB Accreditation for Somatic Cells' Processing, Storage, and Distribution - APN News - November 3rd, 2021
- UAB's Blood and Marrow Transplantation and Cell Therapy Program celebrates 30 years of patient care - UAB News - October 30th, 2021
- Bacterial Infections Linked with Unapproved Stem Cell Treatments - Contagionlive.com - October 25th, 2021
- Global Hematopoietic stem cell transplantation Market Research Report By Share, Size, Top Key Players, Drivers And Forecast To 2027 IMIESA - IMIESA - October 23rd, 2021
- 25 Years Of VST Therapies The Journey Behind The Technology And Innovation - BioProcess Online - October 23rd, 2021
- Cord Blood Registry - October 21st, 2021
- Cord Blood Banking | Parent's Guide to Cord Blood - October 21st, 2021
- Stem Cell Therapy & Treatment - Diseases and Conditions - October 21st, 2021
- Innovative Cancer Treatments, Research in Regenerative Medicine and Gene Therapy to Be Presented at World Cord Blood Day 2021 - PRNewswire - October 21st, 2021
- How does donating stem cells work? - Canadian Blood Services - October 21st, 2021
- GMP Cell Banking Services Market Survey | Know the Post-Pandemic Scenario of the Market - BioSpace - October 21st, 2021
- Global Cord Blood Stem Cells Market 2021 Examination and Industry Growth till 2027 IMIESA - IMIESA - October 19th, 2021
- Worldwide Regenerative Medicine Industry to 2026 - Featuring Allergan, Amgen and Baxter International Among Others - ResearchAndMarkets.com - Yahoo... - October 19th, 2021
- College Student and Retired Teacher to Thank Stem Cell Donors They've Never Met for Saving Their Lives During City of Hope's 45th Bone Marrow... - October 13th, 2021
- Smart Cells: UK's First Umbilical Cord Blood Stem Cell ... - October 11th, 2021
- OrganaBio Adds Perinatal and Adult Tissues for Clinical Manufacturing to its Portfolio of Products for Allogeneic Cell Therapy Development - Business... - October 11th, 2021
- A New Line of Defense in Blood Cancer: Natural Killer Cell Therapy - Curetoday.com - October 11th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WSAW - October 9th, 2021
- Ready to Treat Over 80 Life-Threatening Diseases, Discover the Potential of Cord Blood during World Cord Blood Day 2021 - PRNewswire - October 9th, 2021
- Just what the Webdoctor ordered | Ireland | The Sunday Times - The Times - October 5th, 2021
- Defining the terms: An entry-level guide to the world of cell and gene therapies - San Francisco Business Times - San Francisco Business Times - October 3rd, 2021
- Generate Life Sciences Announces Schedule of Presentations at the ASRM and AABB Annual Meetings - PRNewswire - October 2nd, 2021
- Comprehensive report of Transplantation of Hematopoietic Stem Cells Market Projected to Gain Significant Value by 2026 - Northwest Diamond Notes - October 2nd, 2021
- Bone Marrow-Derived Stem Cells (BMSCS) Market To Gain Significant Revenue and Competitive Outlook UP To 2027 Stillwater Current - Stillwater Current - September 29th, 2021
- Recent Clinical Trials on the Treatment of Myocardial Infarction - GlobeNewswire - September 25th, 2021
- United States Biobanks (Population Based v/s Disease) Markets, Competition Forecast & Opportunities, 2021-2026 - ResearchAndMarkets.com -... - September 25th, 2021
- Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis - DocWire News - September 25th, 2021
- SA Bone Marrow Registry celebrates 30 years of saving lives - Phoenix Sun - September 22nd, 2021
- Therapeutic Solutions International Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in COVID-19 Model... - September 22nd, 2021
- Thawing Equipment Market With Covid-19 Impact on Industry Share, Size, Emerging Technologies, Future Trends, Competitive Analysis | Thermo Fisher... - September 22nd, 2021
- B cells of the immune system discovered in the meninges - EurekAlert - September 18th, 2021
- Leerink Partners Stick to Their Buy Rating for CryoPort Inc By Investing.com - Investing.com - September 17th, 2021
- Stem Cell Equipment Market Demand and SWOT Analysis by 2027 Chart, Worthington Industries, Cesca Therapeutics UNLV The Rebel Yell - UNLV The Rebel... - September 4th, 2021
- LifeCell Community Stem Cell Banking achieves a significant milestone, preserves 60000 qualified cord blood units in its inventory - APN News - August 25th, 2021
- Biobanks Market Size, Share, Growth, Sales Revenue and Key Drivers Analysis Research Report by 2027 The Manomet Current - The Manomet Current - August 14th, 2021
- Cryopreservation Equipment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type - GlobeNewswire - August 14th, 2021
- Later-Generation Cellular Therapies Look Promising in Hematologic Malignancies - Targeted Oncology - August 14th, 2021
- Cryopreservation Equipment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type ; Cryogen Type ; Application ; End User, and... - August 12th, 2021
- Cryo-Cell International to Present at the Q3 Virtual Investor Summit - Yahoo Finance - August 12th, 2021
- Therapeutic Solutions International Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Compared to other... - August 12th, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Market Size, Share, Growth, Analysis, Trend, and Forecast Research Report by 2027 The Manomet Current... - August 12th, 2021
- Acute Myeloid Leukemia Treatment: What You Need to Know - Healthline - August 12th, 2021
- 7 things to know before banking your newborns cord blood - Motherly Inc. - August 12th, 2021
- Cord Blood Banking Service Market is Projected to Showcase Significant Growth USD 2,772 million at CAGR +13% up to 2027| Cord Blood America, Inc., CBR... - July 29th, 2021
- Be wary of stem cell treatments; blood pressure meds help with dementia - Hometown Focus - July 29th, 2021
- Protein Discovery Links Together Two Forms of ALS - Technology Networks - July 29th, 2021